Skip to content

BIOS Capital Management, LP

Follow

13F filer, CIK 1813845, Fort Worth, TX

BIOS Capital Management, LP reported $34,170,550 across 6 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-13.

Accepted , ingested 13F-HR 0001813845-26-000009

Period
2026-09-30
Reported value
$34.2M
Holdings
6
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
LTRNreduced-13,502-$13.6K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001813845-26-000009, largest first. % of portfolio is the value over $34,170,550, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
IRDOPUS GENETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 995,249 shares; 2025Q1: 995,249 shares; 2025Q2: 3,683,429 shares; 2025Q3: 3,683,429 shares; 2025Q4: 3,683,429 shares; 2026Q1: 3,683,429 shares; 2026Q2: 3,683,429 shares; 2026Q3: 3,683,429 shares 3,683,429$17.8M52.17%0Timeline
ACTUACTUATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 9,893,651 shares; 2025Q1: 9,893,651 shares; 2025Q2: 9,965,079 shares; 2025Q3: 10,049,996 shares; 2025Q4: 10,049,996 shares; 2026Q1: 10,049,996 shares; 2026Q2: 10,049,996 shares; 2026Q3: 10,049,996 shares 10,049,996$7.84M22.94%0Timeline
CGTXCOGNITION THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,000,000 shares; 2025Q1: 6,000,000 shares; 2025Q2: 6,000,000 shares; 2025Q3: 6,000,000 shares; 2025Q4: 6,000,000 shares; 2026Q1: 6,000,000 shares; 2026Q2: 6,000,000 shares; 2026Q3: 6,000,000 shares 6,000,000$5.76M16.86%0Timeline
RNTXREIN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,690,751 shares; 2025Q1: 1,690,751 shares; 2025Q2: 1,690,751 shares; 2025Q3: 1,690,751 shares; 2025Q4: 1,690,751 shares; 2026Q1: 1,982,375 shares; 2026Q2: 2,982,375 shares; 2026Q3: 2,982,375 shares 2,982,375$2.4M7.02%0Timeline
LTRNLANTERN PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 1,207,709 shares; 2025Q1: 1,207,709 shares; 2025Q2: 1,075,952 shares; 2025Q3: 1,015,715 shares; 2025Q4: 1,009,507 shares; 2026Q1: 864,435 shares; 2026Q2: 249,397 shares; 2026Q3: 235,895 shares 235,895$238K0.7%-13,502Timeline
INABIN8BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 253,417 shares; 2026Q1: 167,805 shares; 2026Q2: 80,957 shares; 2026Q3: 80,957 shares 80,957$108K0.32%0Timeline

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001813845-26-000009 base2026-11-13